The Role of Molecular Imaging in Drug Discovery and Development

@article{Hargreaves2008TheRO,
  title={The Role of Molecular Imaging in Drug Discovery and Development},
  author={R. J. Hargreaves},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2008},
  volume={83}
}
  • R. Hargreaves
  • Published 2008
  • Medicine
  • Clinical Pharmacology & Therapeutics
Molecular imaging biomarkers are playing an increasingly important role in efforts to increase the probability of success of drug candidates by helping to validate novel drug targets in support of proof‐of‐concept testing early in the drug discovery and development process. By facilitating better and faster decision‐making, molecule and mechanism–based failures can be identified and eliminated from a research portfolio early in development thereby focusing research efforts on the best drug… Expand
View on Wiley
ncbi.nlm.nih.gov
116 Citations
Background Citations
19
Methods Citations
7

Paper Mentions

Blog Post
exploring drug discovery and pharmacology
psique
5 April 2008

116 Citations

Citation Type

Citation Type

Imaging in Drug Development
TLDR
This chapter covers the promise and challenges of using imaging biomarkers in drug development with examples from oncology, cardiovascular disease, respiratory disease, bone biology, and central nervous system disorders. Expand
Optimizing Central Nervous System Drug Development Using Molecular Imaging
TLDR
CNS imaging biomarkers have the potential to drive new medical care practices for patients in the latent phases of progressive neurodegenerative disorders by enabling the detection, preventative treatment, and tracking of disease in a paradigm shift from today's approaches. Expand
From biomarker strategies to biomarker activities and back.
TLDR
This review outlines the rational question-based drug development strategy in which biomarker data drive decisions on which drug candidates to progress to clinical testing, and the intensive search for and use of high-quality biomarkers. Expand
Translational neuroimaging of the CNS: novel pathways to drug development.
TLDR
A brief review of examples of the new wave of neuroimaging studies that engender useful biomarkers of disease for translational research. Expand
Clinical Application of Molecular Features in Therapeutic Selection and Drug Development
TLDR
This chapter focuses on a specific type of biomarkers: the ones useful for therapeutic decision and therapeutic drug development in the clinical setting, and methodologies on biomarkers evaluation for clinical utility and analytical validity. Expand
The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system
TLDR
This study is focused on the high attrition rate in discovery and development of oncology and central nervous system medicines, because the failure rate of these medicines is higher than others. Expand
Imaging as a Tumor Biomarker in Oncology Drug Trials for Lung Cancer: The FDA Perspective
TLDR
The US Food and Drug Administration is working with the pharmaceutical industry, academia, and sister stakeholders in the government, primarily through collaborative educational and research efforts, to identify how imaging can serve this function. Expand
Translational PET imaging research
TLDR
CNS PET imaging can also play an important role in the clinical investigation of the neuropharmacological basis of psychiatric disease and the optimization of drug therapy. Expand
Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET)
TLDR
The ADDMI interest group launched their efforts at the 2016 World Molecular Imaging Congress by hosting a session of invited lectures on translational positron emission tomography (PET) imaging in the central nervous system and frames the role of translational imaging biomarker strategies in the drug discovery and development process. Expand
Imaging as a Localized Biomarker: Opportunities and Challenges
In recent years, the concept of imaging biomarkers is increasingly being utilized in drug development and for producing images of physiological and physicochemical processes in a living subject.… Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Optical molecular imaging in drug discovery and clinical development
TLDR
The authors focus the interest of this review on optical molecular imaging technology as well as reviewing how this technology is being integrated in various therapeutic areas, and how it has started to impact the preclinical drug discovery process. Expand
Clinical biomarkers in drug discovery and development
TLDR
Clinically useful biomarkers are required to inform regulatory and therapeutic decision making regarding candidate drugs and their indications in order to help bring new medicines to the right patients faster than they are today. Expand
MOLECULAR IMAGING IN DRUG DISCOVERY AND DEVELOPMENT
NATURE REVIEWS | DRUG DISCOVERY VOLUME 2 | FEBRUARY 2003 | 123 Imagine seeing a specific molecular target in a live animal, following a drug’s distribution in the same animal and quantitating the… Expand
Small animal imaging in drug development.
TLDR
Better mechanistic understanding of disease through mapping of the human and mouse genomes enables rethinking of human infirmity, and the ability to study those animals noninvasively and quantitatively with new, high-resolution imaging devices provides the most relevant milieu in which to find and examine new therapies. Expand
A role for fMRI in optimizing CNS drug development
Drug development today needs to balance agility, speed and risk in defining the probability of success for molecules, mechanisms and therapeutic concepts. New techniques in functional magnetic… Expand
Role of in vivo imaging of the central nervous system for developing novel drugs.
  • M. A. Rueger, L. Kracht, +9 authors A. Jacobs
  • Medicine
  • The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
  • 2007
TLDR
Various imaging technologies, such as cranial computed tomography (CT), magnetic resonance imaging (MRI) and spectroscopy (MRS), positron emission tomography and single-photon emission computed tomographic (SPECT), with respect to their current applications in non-invasive disease phenotyping and the measurement of therapeutic outcomes in neurology are reviewed. Expand
Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm.
TLDR
Integration of the two disciplines of molecular imaging and molecular medicine, combined with systems-biology approaches to understanding disease complexity, promises to provide predictive, preventative and personalized medicine that will transform healthcare. Expand
The opportunities and challenges of developing imaging biomarkers to study lung function and disease.
  • D. Schuster
  • Medicine
  • American journal of respiratory and critical care medicine
  • 2007
TLDR
To take full advantage of the opportunities presented by state-of-the-art imaging methods, new approaches to analytic and clinical validation must be developed in collaboration with industry, foundation, and federal funding agencies. Expand
Molecular imaging of cardiovascular disease.
TLDR
Key factors spurring the growth of molecular imaging include the application of novel ligand screening methods, emerging new chemistries for conjugation and signal amplification, and nanotechnology, which have fostered substantial growth in ligand development. Expand
Emerging concepts in molecular MRI.
TLDR
High-throughput screens of nanoparticle libraries have identified nanoparticles that act as novel contrast agents and which can be targeted with enhanced diagnostic specificity and range, and other specialized MR probes have been developed to image enzyme activity in vivo. Expand
...
1
2
3
...